PL360406A1 - Analogi glukanopodobnego peptydu-1 - Google Patents

Analogi glukanopodobnego peptydu-1

Info

Publication number
PL360406A1
PL360406A1 PL01360406A PL36040601A PL360406A1 PL 360406 A1 PL360406 A1 PL 360406A1 PL 01360406 A PL01360406 A PL 01360406A PL 36040601 A PL36040601 A PL 36040601A PL 360406 A1 PL360406 A1 PL 360406A1
Authority
PL
Poland
Prior art keywords
glucagon
peptide
analogs
glp
compounds
Prior art date
Application number
PL01360406A
Other languages
English (en)
Other versions
PL206302B1 (pl
Inventor
Wolfgang Glaesner
Rohn Lee Millican
Original Assignee
Elli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elli Lilly And Company filed Critical Elli Lilly And Company
Publication of PL360406A1 publication Critical patent/PL360406A1/pl
Publication of PL206302B1 publication Critical patent/PL206302B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL360406A 2000-06-16 2001-06-01 Związek GLP-1 PL206302B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21217100P 2000-06-16 2000-06-16
US24034900P 2000-10-13 2000-10-13
PCT/US2001/016474 WO2001098331A2 (en) 2000-06-16 2001-06-01 Glucagon-like peptide-1 analogs

Publications (2)

Publication Number Publication Date
PL360406A1 true PL360406A1 (pl) 2004-09-06
PL206302B1 PL206302B1 (pl) 2010-07-30

Family

ID=26906843

Family Applications (1)

Application Number Title Priority Date Filing Date
PL360406A PL206302B1 (pl) 2000-06-16 2001-06-01 Związek GLP-1

Country Status (32)

Country Link
US (2) US7084243B2 (pl)
EP (2) EP1294757B1 (pl)
JP (1) JP4716641B2 (pl)
KR (1) KR100847615B1 (pl)
CN (1) CN100469791C (pl)
AR (1) AR031701A1 (pl)
AT (2) ATE424413T1 (pl)
AU (2) AU2001264791B2 (pl)
BR (1) BR0111562A (pl)
CA (1) CA2412004C (pl)
CY (2) CY1105917T1 (pl)
CZ (1) CZ304002B6 (pl)
DE (2) DE60137876D1 (pl)
DK (2) DK1294757T3 (pl)
DZ (1) DZ3388A1 (pl)
EA (1) EA008837B1 (pl)
EG (1) EG24755A (pl)
ES (2) ES2321439T3 (pl)
HR (1) HRP20020996B1 (pl)
HU (2) HU229108B1 (pl)
IL (2) IL153453A0 (pl)
MX (1) MXPA02012203A (pl)
MY (1) MY137350A (pl)
NO (1) NO330686B1 (pl)
NZ (1) NZ522330A (pl)
PE (1) PE20011363A1 (pl)
PL (1) PL206302B1 (pl)
PT (2) PT1294757E (pl)
SI (1) SI1695983T1 (pl)
SK (1) SK287757B6 (pl)
TW (1) TWI321134B (pl)
WO (1) WO2001098331A2 (pl)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001264791B2 (en) * 2000-06-16 2006-11-23 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DK1326630T3 (da) * 2000-09-18 2008-09-15 Sanos Bioscience As Anvendelse af GLP-2-peptider
DK1412384T3 (da) * 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
WO2003018516A2 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1572892A4 (en) * 2001-10-18 2007-08-22 Bristol Myers Squibb Co HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
ATE352312T1 (de) * 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
CA2473340C (en) * 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2003103572A2 (en) * 2002-06-04 2003-12-18 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20050059605A1 (en) * 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
US20060217300A1 (en) 2003-02-19 2006-09-28 Biomeasure, Incorporated Analogues of glp-1
CA2525574C (en) 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
JP4936884B2 (ja) * 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7521527B2 (en) * 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
CA2552526A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
SI2308977T1 (sl) 2004-04-30 2013-06-28 Dow Agrosciences Llc Novi geni z rezistenco na herbicide
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
US8710181B2 (en) * 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
WO2006074600A1 (en) 2005-01-14 2006-07-20 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006098524A1 (ja) * 2005-03-18 2006-09-21 Ajinomoto Co., Inc. ストレスによる腸疾患の予防・治療剤
KR101011081B1 (ko) * 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Ｐｅｇ화된 ｇｌｐ-1 화합물
TWI364292B (en) 2005-06-30 2012-05-21 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
ES2612119T3 (es) 2005-10-28 2017-05-12 Dow Agrosciences Llc Nuevos genes de resistencia a herbicidas
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2008063203A2 (en) * 2006-01-27 2008-05-29 Whitehead Institute For Biomedical Research Compositions and methods for efficient gene silencing in plants
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
CA2800389A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
CA2655923A1 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof
BRPI0714334A2 (pt) * 2006-07-18 2013-05-14 Centocor Inc mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
KR100851560B1 (ko) * 2006-12-27 2008-08-11 고려대학교 산학협력단 새로운 글루카곤 유사 펩타이드-1 (ｇｌｐ-1) 작용제 및 그용도
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CN101041693B (zh) * 2007-02-06 2011-08-17 珠海联邦制药股份有限公司 一种降血糖多肽及其应用
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
US8464239B2 (en) * 2007-06-11 2013-06-11 Red Hat, Inc. Real-time installation and/or configuration assistant
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
DK2211842T3 (en) * 2007-10-24 2015-09-21 Mannkind Corp An inhalable dry powder formulation COMPREHENSIVE GLP-1 FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DIABETES BY pulmonary delivery
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
EP2214647A2 (en) * 2007-10-24 2010-08-11 MannKind Corporation Delivery of active agents
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
JP5775450B2 (ja) 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
AR072159A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CN101337989B (zh) * 2008-08-28 2012-10-24 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
EP2344519B1 (en) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
BRPI1014508A2 (pt) 2009-06-16 2016-04-05 Univ Indiana Res & Tech Corp análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
BR112012003327A2 (pt) 2009-08-14 2017-06-06 Phasebio Pharmaceuticals Inc peptídeos intestinais vasoativos modificados
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
EP2495255A4 (en) * 2009-10-30 2013-05-15 Otsuka Chemical Co Ltd GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
WO2011143788A1 (en) * 2010-05-17 2011-11-24 Zhejiang Beta Pharma Inc. Novel glucagon like peptide analogs, composition, and method of use
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
CA2803646A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
CN102180963B (zh) * 2011-04-22 2014-06-25 中国药科大学 胰高血糖素样肽-1(glp-1)类似物及其应用
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX347703B (es) 2011-06-22 2017-05-09 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1.
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
CA2849673A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
CN103087179A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087176A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087178A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087175A (zh) * 2012-11-30 2013-05-08 中国药科大学 新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087177A (zh) * 2012-11-30 2013-05-08 中国药科大学 一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
CN104262481B (zh) * 2013-08-09 2018-02-09 天津药物研究院有限公司 一种侧链修饰的长效glp‑1类似物的制备方法及其应用
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MD20170055A2 (ro) * 2014-10-24 2017-09-30 Merck Sharp & Dohme Corp Co-agonişti ai receptorilor glucagonului şi GLP-1
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN116059389A (zh) * 2015-12-31 2023-05-05 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
DK3774862T3 (da) 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN113195524A (zh) 2018-10-11 2021-07-30 因塔西亚治疗公司 人类胰淀素类似物多肽和使用方法
KR20210081376A (ko) 2018-10-30 2021-07-01 지아닝 리우 Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
AU2001264791B2 (en) * 2000-06-16 2006-11-23 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
EP2022505B1 (en) * 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
AU2010279305A1 (en) * 2009-08-07 2012-03-01 Perry Felix Method and apparatus for surface and subsurface sanitizing of food products in a cooking appliance using ultraviolet light

Also Published As

Publication number Publication date
US20030220243A1 (en) 2003-11-27
EP1294757A2 (en) 2003-03-26
HK1055121A1 (en) 2003-12-24
ATE346093T1 (de) 2006-12-15
SK17782002A3 (sk) 2003-07-01
NZ522330A (en) 2004-11-26
DE60124710T2 (de) 2007-09-13
WO2001098331A2 (en) 2001-12-27
MY137350A (en) 2009-01-30
EA200300026A1 (ru) 2003-04-24
EP1294757B1 (en) 2006-11-22
PL206302B1 (pl) 2010-07-30
US7498308B2 (en) 2009-03-03
DE60137876D1 (de) 2009-04-16
SK287757B6 (sk) 2011-08-04
JP4716641B2 (ja) 2011-07-06
IL153453A (en) 2009-11-18
CA2412004C (en) 2010-12-21
IL153453A0 (en) 2003-07-06
EG24755A (en) 2010-07-26
JP2004501162A (ja) 2004-01-15
CA2412004A1 (en) 2001-12-27
HUP0301212A3 (en) 2004-09-28
BR0111562A (pt) 2003-04-15
CY1109061T1 (el) 2014-07-02
CZ304002B6 (cs) 2013-08-14
AU6479101A (en) 2002-01-02
TWI321134B (en) 2010-03-01
HRP20020996A2 (en) 2004-02-29
EP1695983B1 (en) 2009-03-04
WO2001098331A3 (en) 2003-01-03
PE20011363A1 (es) 2002-01-15
ES2321439T3 (es) 2009-06-05
EA008837B1 (ru) 2007-08-31
AR031701A1 (es) 2003-10-01
ES2275685T3 (es) 2007-06-16
DZ3388A1 (fr) 2001-12-27
US20060263849A1 (en) 2006-11-23
EP1695983A3 (en) 2007-02-21
NO20025949L (no) 2002-12-11
DK1695983T3 (da) 2009-05-18
CZ20024088A3 (cs) 2003-05-14
DK1294757T3 (da) 2007-03-19
NO20025949D0 (no) 2002-12-11
US7084243B2 (en) 2006-08-01
HUP0301212A2 (hu) 2003-08-28
HRP20020996B1 (hr) 2011-09-30
KR100847615B1 (ko) 2008-07-21
SI1695983T1 (sl) 2009-08-31
DE60124710D1 (de) 2007-01-04
NO330686B1 (no) 2011-06-06
CN100469791C (zh) 2009-03-18
CN1468258A (zh) 2004-01-14
HU229208B1 (en) 2013-09-30
PT1294757E (pt) 2007-02-28
HU229108B1 (en) 2013-09-30
EP1695983A2 (en) 2006-08-30
MXPA02012203A (es) 2003-06-06
ATE424413T1 (de) 2009-03-15
KR20030009537A (ko) 2003-01-29
PT1695983E (pt) 2009-05-05
CY1105917T1 (el) 2011-04-06
AU2001264791B2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
EG24755A (en) Glucagon-like peptide -1 analogs.
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
IL251270B (en) 40-o-(2-hydroxyethyl)-rapamycin in combination with exemestane for use in the treatment of hormone receptor positive tumor
HUP0204281A3 (en) Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
TW263423B (pl)
KR950027550U (ko) 클로즈 가이드(Cloth guide)의 경사안내로울러 좌. 우 이송장치
NO942363D0 (pl)
WO1999053064A3 (en) Methods of delivering glp-1
ATE196631T1 (de) Xamonelin-tartrat
UA88862C2 (en) Glucagon-like peptide-1 analogs
ZA200304047B (en) Analogues of GLP-1.
Manukhin On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya
ZA997090B (en) "A composition for the treatment of wood".
ZA946451B (en) Fabric treatment composition.
ZA200004651B (en) Xylitol compositions for treating upper respiratory conditions.

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20140601